Beam Therapeutics Inc. (NASDAQ: BEAM) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Beam Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.65, Beam Therapeutics Inc. trades at 14.8x sales and 2.3x book value. Over the last twelve months it generated about $144M of revenue and a net loss of $102M. It runs an operating margin of -267.7% and a net margin of -73.0%. It shows return on equity of -9.7%, return on invested capital of -32.6% and a free cash flow yield of -18.5%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 13.00. Over the past 52 weeks the share price ranged from $20.23 to $38.26, with a beta of 2.22.
Beam Therapeutics Inc. does not currently pay a dividend.
28 Wall Street analyst ratings cover the stock: 19 Buy, 8 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.